This is good on the Ox/AZ vaccine journey

Very pleased to be the academic lead on this. A great platform to advance drug discovery and develop spinout opportunities alongside world-leading companies

These updates are great if you like to keep abreast of the latest advances in med chem

Kynos Therapeutics, a life sciences spin-out from The University of Edinburgh, has emerged from 'stealth mode' with £9m to finance its next phase of growth insider.co.uk/news/edinburgh…

Delighted to announce this investment into @KynosTxLtd

New portfolio company @KynosTxLtd with @epidarex Scottish Enterprise Damian Mole Scott Webster. Excited to support & you can read more here: bit.ly/3NVhsmo. #backinginnovation 👇 thetimes.co.uk/article/kynos-…

Great news on #WorldHealthDay with investment in new co @KynosTxLtd. Excited to support & you can read more here: bit.ly/3NVhsmo. #backinginnovation @epidarex Scottish Enterprise 👇 University of Edinburgh life sciences spin-out secures major £9m injection scotsman.com/business/unive…

"Supporting companies such as Kynos Therapeutics to progress its ground-breaking medical research is a priority for Scottish Enterprise" - our Director of Growth Investments, Kerry Sharp on the The University of Edinburgh spin-out's financing announcement today: bit.ly/3jejsIr

Really happy to have support from Scottish Enterprise to build our company

Enamine is resuming work. Please review the new statement from our Founder and CEO, Andrey Tolmachev. bit.ly/3KkVeIq

heraldscotland.com/business_hq/20…

labiotech.eu/trends-news/an…

😥

Kynos is rapidly building momentum towards the clinic. Alison’s experience across large pharma and #biotech covers #finance at the #operational level as well as a #strategic outlook. A breadth of skill and experience to support Kynos achieve a strong position in the near future.

... and on the same day here are the encouraging clinical trial results from the drug that we developed to reduce cortisol action in the brain of patients with dementia Scott Webster actinogen.com.au

Proud to have been part of the team responsible for developing this medicine. Really encouraging results for those affected by Alzheimer's disease.

Jonathan is an excellent addition to the @KynosTxLtd team. I look forward to working together to build further success.